Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 94Neoplasm Metastasis 6Breast Diseases 3Prostatic Neoplasms 2Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Cancer Metastatic 2Triple Negative Breast Neoplasms 1Recurrence 1Primary Breast Cancer ER+ve 1Pancreatic Neoplasms 1Neoplasms 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Multiple Endocrine Neoplasia Type 1 1Metastatic Beast Cancer 1Mammary Neoplasms, Animal 1Locoregional Recurrence 1Lethal Congenital Contracture Syndrome 2 1Hyperglycemia 1Hormone Receptor Positive Malignant Neoplasm of Breast 1HER2-positive Breast Cancer 1Granulosa cell tumor of the ovary 1Estrogen-receptor Positive Invasive Metastatic Breast Cancer 1Endometrial Stromal Tumors 1Endometrial Hyperplasia 1ER+ Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Fulvestrant 8olaparib 4Capecitabine 4pyrotinib 3Docetaxel 3toripalimab 2Vinorelbine 2Trastuzumab 2Letrozole 2Injections 2Goserelin 2Alpelisib 2vandetanib 1trastuzumab deruxtecan 1talazoparib 1sacituzumab govitecan 1pembrolizumab 1neratinib 1liposomal doxorubicin 1exemestane 1eribulin 1dalpiciclib 1ceralasertib 1cediranib 1capivasertib 1abemaciclib 1Tablets 1Paclitaxel 1Moxifloxacin 1Lead 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Breast Cancer × exemestane × Clear all
NCT02069093 2017-02-13

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Novartis

Phase 2 Completed
92 enrolled 9 charts
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡